
Hair transplant explained: Step-by-step guide to how it really works
There are two primary techniques:FUT (Follicular Unit Transplantation) – Involves removing a strip of scalp and dissecting it into grafts under a microscope. FUE (Follicular Unit Excision) – Involves individually excising hair follicles using a micro-punch tool.Each method uses your natural hair, which continues to grow even after transplantation.STEP-BY-STEP HAIR TRANSPLANT PROCEDURELet's walk through each phase of a typical hair transplant, from consultation to recovery.1. INITIAL CONSULTATION AND SCALP ANALYSISThis is where your hair restoration journey begins.The surgeon evaluates your hair loss pattern and scalp health. A trichoscopy test may be done to assess follicular density. Donor area strength is analysed to determine the best-suited technique (FUE or FUT). Photos are taken for planning and progress tracking. Expectations, risks, pricing, and post-operative care are discussed in detail.advertisementThis is also the right time to ask questions and set realistic expectations.2. HAIRLINE DESIGN AND SURGICAL PLANNINGA successful transplant is as much about art as it is science.The surgeon designs a custom hairline to suit your facial features and age. The required number of grafts is estimated to achieve the desired density. Future hair loss is considered to ensure long-lasting, natural-looking results. 3. PREPARATION AND LOCAL ANAESTHESIAOn the day of the procedure:Hair is trimmed short in both donor and recipient areas, unless an unshaven or long-hair transplant is planned (especially common for female patients who prefer not to shave). A test dose is given first to rule out any allergy to the local anaesthetic. Once cleared, local anaesthesia is administered to numb the scalp. There may be minor discomfort during the injection, but the procedure itself is painless. You remain awake and relaxed throughout. 4. HARVESTING HAIR FOLLICLES (FUE OR FUT)This is the core of the procedure.FUE (Follicular Unit Excision): Individual follicles are excised using a micro-punch (0.6–1 mm), creating dot-like scars scattered across the donor zone. Each graft has 1–4 hairs and is preserved carefully. FUT (Follicular Unit Transplantation): A strip of scalp is surgically removed from the donor zone and dissected into follicular units. FUT typically yields more grafts from the central core area, where the best-quality follicles reside, and preserves more donor area for future sessions.advertisementEach technique has its pros and cons. It is advisable to let the surgeon decide the most suitable method based on your hair loss pattern, donor reserve, and long-term planning.5. GRAFT SORTING AND PRESERVATIONOnce harvested:Grafts are examined under magnification to ensure their integrity. They are sorted based on size—single, double, or multiple hair grafts. All grafts are stored in an isotonic solution to maintain hydration and viability before implantation.Proper handling here is key to graft survival and natural growth.6. MAKING RECIPIENT SITE INCISIONSTiny slits are made in the recipient area using fine needles or blades.Factors considered:Angle and direction for natural-looking hair growth. Proper spacing to avoid overcrowding and to maintain blood supply. Density planning based on graft availability.Think of this step as planting seeds—precision defines the outcome.7. IMPLANTING THE HAIR GRAFTSThis step involves placing each graft into the recipient sites:advertisementSingle-hair grafts are used at the hairline for a soft, natural look. Multi-hair grafts add density to the area behind the hairline.The process can take several hours, depending on the graft count, usually ranging from 1,000 to 4,000.Hair transplants have evolved significantly, offering lasting and natural results for those dealing with hair loss. But the success of the procedure depends on key factors:Choosing a qualified and experienced hair transplant surgeon (preferably a board-certified plastic surgeon or dermatologist). Ensuring that all excisional and incisional steps are performed by the surgeon. Careful surgical planning tailored to your unique hair pattern. Diligent post-procedure care for long-term results.It's not just about looking better—it's about feeling like yourself again. Take your time, research thoroughly, and step into your transformation informed and empowered.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
12 hours ago
- Time of India
UnitedHealth Group (UNH) stock jumps 12% after Buffett's $1.6B stake — forecast predicts 24% upside, is UNH a must-buy?
UnitedHealth Group (UNH) shares soared 12% on August 15, 2025, after Warren Buffett's Berkshire Hathaway revealed a $1.6 billion stake of over 5 million shares. The surge marks the stock's biggest jump in five years, bringing it back above the key $300 level for the first time since mid-July. Analysts now see potential upside of more than 20%, making UNH a 'must-buy' for investors looking for stability in a turbulent healthcare market. UnitedHealth Group (UNH) stock jumped 12% on August 15, 2025, after Warren Buffett's Berkshire Hathaway revealed a $1.6 billion stake, snapping the insurer out of a recent slump. Shares climbed past the $300 mark, the first time since mid-July, and analysts are now forecasting a potential 24% upside. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Stock Price (Aug 15, 2025): $302.76 Intraday High/Low: $307.90 / $295 After-Hours Gain: 11% Shares Purchased by Berkshire Hathaway: 5 million+ Berkshire Cash Reserve: $344 billion Buffett's Strategic Bet: A Signal of Long-Term Confidence Buffett's broader portfolio strategy Berkshire trimmed Apple (AAPL) and Bank of America (BAC) positions Initiated new stakes in homebuilders like D.R. Horton (DHI) and Lennar Corp Added shares in industrial steelmaker Nucor (NUE) Market Reaction: Berkshire Hathaway's Portfolio Moves Current Price: $302.65 USD $302.65 USD Price Change: +$31.16 (+11.48%) from previous close of $271.49 +$31.16 (+11.48%) from previous close of $271.49 Opening Price: $301.00 USD $301.00 USD Intraday High: $307.90 USD $307.90 USD Intraday Low: $295.00 USD $295.00 USD After-Hours Movement: Shares surged following Buffett's investment announcement Shares surged following Buffett's investment announcement Trading Volume: 30,116,349 shares 30,116,349 shares Key Trigger: Berkshire Hathaway bought over 5 million UnitedHealth shares, valued at ~$1.6 billion Berkshire Hathaway bought over 5 million UnitedHealth shares, valued at ~$1.6 billion Market Sentiment: Strong investor confidence despite regulatory scrutiny over Medicare Advantage billing practices Strong investor confidence despite regulatory scrutiny over Medicare Advantage billing practices Implication: Seen as a vote of confidence in UnitedHealth's long-term growth and stability What this means for UnitedHealth and investors Tired of too many ads? Remove Ads Confidence boost amid regulatory scrutiny: Investors may view Buffett's vote as a backstop to share price volatility. Potential support for growth initiatives: Medicare Advantage expansion and other healthcare services could receive renewed focus. Short-term price resilience: The $300 psychological level may act as a recovered support level, with resistance near $342 and potential upside toward $376.84. Stock forecast and outlook Near-term resistance: $342 $342 Mid-term gap fill: $376.84 $376.84 Long-term former support: $438.50 Expert Takeaway: FAQs: UnitedHealth Group (UNH) stock soared on August 15, 2025, hitting its best day in five years after Warren Buffett's Berkshire Hathaway disclosed a $1.6 billion purchase of over 5 million shares. The move sent the healthcare giant's stock up 12% in after-hours trading, signaling strong investor confidence despite recent regulatory and financial say Buffett's entry comes at a critical time, as UnitedHealth navigates regulatory scrutiny over Medicare Advantage billing practices and has faced a roughly 15% decline in stock value over the past Analysts now see potential upside of more thanfor investors looking for stability in a turbulent healthcare see this as a major endorsement from one of the world's most respected investors, suggesting that UnitedHealth's long-term growth prospects remain robust, particularly in its diversified healthcare services and expanding Medicare Advantage surge also reflects broader market optimism, as institutional and retail investors often follow Buffett's high-profile moves, betting on stability and resilience in a volatile healthcare investment comes as UnitedHealth navigates a challenging landscape. The company has faced federal scrutiny over its Medicare Advantage billing practices and a notable drop in stock value over the past year. Yet, Berkshire Hathaway's purchase is being interpreted by analysts as a robust vote of confidence."Buffett rarely invests on a whim," says financial analyst Linda Chen of Apex Capital. "This signals that UnitedHealth's fundamentals, especially its diversified healthcare services and strong market position, remain highly attractive for long-term investors."This acquisition is part of a strategic reshuffle at Berkshire Hathaway. In Q2 2025:The firm retains a cash reserve of $344 billion, giving Buffett ample room for strategic bets in undervalued or high-potential stock closed at, climbingin after-hours trading on August 15. Intraday, the stock hit a high ofand a low of, with a trading volume exceeding. The sharp uptick reflects investor optimism that Buffett's involvement could stabilize sentiment and boost confidence in UnitedHealth's growth acquisition is part of broader strategic changes in Berkshire Hathaway's portfolio. According to the latest 13F filing, Buffett's firm reduced its stake in Apple by 7%, while initiating new positions in homebuilders likeand, and industrial steel producer. The moves suggest a diversification strategy into sectors with potential long-term gains, even as Berkshire holds a substantial cash reserve ofBuffett's entry could stabilize market sentiment and attract additional institutional interest. For UnitedHealth, the implications include:However, regulatory risks remain. Investigations into Medicare Advantage billing practices could still impact earnings and valuation in the near analysts see UNH trading above its 50-day Simple Moving Average (SMA) for the first time since April, signaling a possible bullish trend. Key targets include:While short-term traders may celebrate the 11% surge, seasoned investors recognize Buffett's hallmark: patient, long-term investing. His move is less about immediate gains and more about UNH's enduring market position and operational short-term traders may celebrate the after-hours surge, seasoned investors recognize Buffett's hallmark: patient, long-term investing. This move underscores his confidence not in immediate gains but in UnitedHealth's enduring market position, operational efficiency, and healthcare sector growth did Warren Buffett invest in UnitedHealth stock today?Buffett bought over $1.6B in UnitedHealth shares, showing confidence in the company's growth and long-term did UnitedHealth shares react after Buffett's purchase?UnitedHealth stock soared 11% after-hours, reaching $302.76, reflecting strong investor optimism.


Time of India
3 days ago
- Time of India
Cohance Lifesciences announces $10 million investment in US-based arm
Cohance Lifesciences on Tuesday announced a strategic investment of USD 10 million (around Rs 87.6 crore) to expand bioconjugation capabilities at its US-based subsidiary, NJ Bio . The investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply, the company said in a statement. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program The common good manufacturing practices (cGMP) compliant bioconjugation suite at NJ Bio's Princeton, New Jersey, facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Top 32 Most Beautiful Women In The World Undo "The investment ... strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster," Vivek Sharma, Executive Chairman, Cohance Lifesciences, said. In a separate statement, Cohance announced a Rs 23 crore investment and significant progress on its new oligonucleotide building block manufacturing facility in Hyderabad . Live Events "Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply," the company said. Cohance Lifesciences, formerly Suven Pharmaceuticals , is an innovator-focused global Contract Research, Development, and Manufacturing Organization (CRDMO), formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.


News18
4 days ago
- News18
Cohance Lifesciences announces USD 10 mn investment in US-based arm
New Delhi, Aug 12 (PTI) Cohance Lifesciences on Tuesday announced a strategic investment of USD 10 million (around Rs 87.6 crore) to expand bioconjugation capabilities at its US-based subsidiary, NJ Bio. The investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply, the company said in a statement. The common good manufacturing practices (cGMP) compliant bioconjugation suite at NJ Bio's Princeton, New Jersey, facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions, it added. 'The investment … strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster," Vivek Sharma, Executive Chairman, Cohance Lifesciences, said. In a separate statement, Cohance announced a Rs 23 crore investment and significant progress on its new oligonucleotide building block manufacturing facility in Hyderabad. 'Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply," the company said. Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global Contract Research, Development, and Manufacturing Organization (CRDMO), formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. PTI MSS MR view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.